{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:24:14Z","timestamp":1785770654083,"version":"3.56.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1097\/01.jcp.0000085406.08426.a8","type":"journal-article","created":{"date-parts":[[2003,8,21]],"date-time":"2003-08-21T17:38:06Z","timestamp":1061487486000},"page":"342-348","source":"Crossref","is-referenced-by-count":81,"title":["Effectiveness of Rapid Initial Dose Escalation of up to Forty Milligrams per Day of Oral Olanzapine in Acute Agitation"],"prefix":"10.1097","volume":"23","author":[{"given":"Robert W.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Kinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald A.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210128","first-page":"88","article-title":"The expert consensus guideline series. Treatment of behavioral emergencies.","volume":"May","author":"Allen","year":"2001","journal-title":"J Postgrad Med"},{"key":"R2-5-20210128","first-page":"11","article-title":"Managing the agitated psychotic patient: a reappraisal of the evidence.","volume":"61","author":"Allen","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R3-5-20210128","first-page":"27","article-title":"Rationale and guidelines for the inpatient treatment of acute psychosis.","volume":"61","author":"Feifel","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R4-5-20210128","first-page":"17","article-title":"Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.","volume":"62","author":"Kinon","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.","volume":"159","author":"Volavka","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R8-5-20210128","first-page":"S3S11","article-title":"Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications.","volume":"63","author":"Keck","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004714-199906000-00015","article-title":"Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.","volume":"19","author":"Fanous","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R10-5-20210128","first-page":"12","article-title":"Rapid tranquilization with olanzapine in acute psychosis: a case series.","volume":"62","author":"Karagianis","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1176\/ajp.154.11.1626","article-title":"High-dose olanzapine for treatment-refractory schizophrenia.","volume":"154","author":"Sheitman","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R12-5-20210128","first-page":"21S","article-title":"High dose olanzapine vs. clozapine in treatment-resistant schizophrenia: a pilot double-blind crossover study.","volume":"51","author":"Conley","year":"2002","journal-title":"Biol Psychiatry"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1176\/jnp.9.4.541","article-title":"The Overt Agitation Severity Scale for the objective rating of agitation.","volume":"9","author":"Yudofsky","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1185\/03007999009111492","article-title":"Zuclopenthixol acetate (5% in \u201cViscoleo\u201d): single-dose treatment for acutely disturbed psychotic patients.","volume":"12","author":"Chakravarti","year":"1990","journal-title":"Curr Med Res Opin"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0033-3182(96)71517-7","article-title":"Validation of a cognitive test for delirium in medical ICU patients.","volume":"37","author":"Hart","year":"1996","journal-title":"Psychosomatics"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0022-3999(97)00140-2","article-title":"Abbreviated cognitive test for delirium.","volume":"43","author":"Hart","year":"1997","journal-title":"J Psychosom"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0893-133X(01)00365-7","article-title":"Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind randomized study in acutely agitated patients with dementia.","volume":"26","author":"Meehan","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.","volume":"158","author":"Wright","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00004714-200108000-00006","article-title":"A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.","volume":"21","author":"Meehan","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular (IM) olanzapine and IM haloperidol in the treatment of acute agitation in schizophrenia.","volume":"59","author":"Breier","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0006-3223(99)00273-5","article-title":"Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo.","volume":"47","author":"Sharpley","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0006-3223(98)00372-2","article-title":"Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.","volume":"46","author":"Salin-Pascual","year":"1999","journal-title":"Biol Psychiatry"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"Beasley","year":"1996","journal-title":"Neurospychopharmacology"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania.","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R30-5-20210128","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","article-title":"Olanzapine versus divalproex in the treatment of acute mania.","volume":"159","author":"Tohen","year":"2002","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007632-200308150-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:33:59Z","timestamp":1785767639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200308000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000085406.08426.a8","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}